Exclusive: Flagship snags another CEO-partner, on a personal mission, to lead its tRNA boat
Flagship’s Alltrna bet, an RNA follow-up to its skyrocketing success with Moderna, has a new face at the helm as of today and the nascent CEO is on a personal mission.
Michelle Werner became a member of the rare disease community two years ago when her son was diagnosed with a rare genetic condition. The 20-year pharma veteran is turning in her Novartis hat, as head of the Swiss giant’s solid tumor unit, to take on the dual post of CEO of Alltrna and CEO-partner at the biotech’s incubator, Flagship Pioneering.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.